The objective of this study was to estimate if inositol monophosphatase 2 (IMPA2) downregulation refers to a favorable outcome in metastatic ccRCC receiving mTOR inhibitor treatment. The gene discussed is IMPA2; the disease is nonpapillary renal cell carcinoma.